ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients

Journal of Hepatology

Volumn 67, Issue 3, 2017, Pages 585-602

  Belli, Luca S ^a,b   Duvoux, Christophe ^c   Berenguer, Marina ^k   Berg, Thomas ^d   Coilly, Audrey ^j   Colle, Isabelle ⁱ   Fagiuoli, Stefano ^f   Khoo, Saye ^g   Pageaux, Georges Philippe ^h   Puoti, Massimo ^a   Samuel, Didier ^j   Strazzabosco, Mario ^b,e  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e YALE UNIVERSITY   (United States)

^f PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

^h HÔPITAL SAINT ELOI   (France)

ⁱ GHENT UNIVERSITY   (Belgium)

^j HÔPITAL PAUL BROUSSE   (France)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

more..

Author keywords

Antiviral agents; Guidelines; Hepatitis C, chronic; Interferons; Liver failure; Liver transplant candidate; Liver transplant recipient; Liver transplantation; Recurrent hepatitis C; Waiting lists

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; DIRECT ACTING ANTIVIRAL AGENT; GRAZOPREVIR; IMMUNOSUPPRESSIVE AGENT; LEDIPASVIR; PARITAPREVIR; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; VELPATASVIR;

CLINICAL PRACTICE; DECOMPENSATED LIVER CIRRHOSIS; DRUG SAFETY; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HUMAN; INTESTINE GRAFT; LIVER CELL CARCINOMA; LIVER GRAFT; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; REINFECTION; REVIEW; SEVERE RENAL IMPAIRMENT; SURGICAL PATIENT; CONSENSUS; DRUG INTERACTION; LIVER TRANSPLANTATION;

ANTIVIRAL AGENTS; CONSENSUS; DRUG INTERACTIONS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION;

EID: 85020047350     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.03.006     Document Type: Review

References (68)

1. Berenguer, M., Ferrell, L., Watson, J., Prieto, M., Kim, M., Rayon, M., et al. HCV related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 32 (2000), 673–684.
2. Gallegos-Orozco, J.F., Yosephy, A., Noble, B., Aqel, B.A., Byrne, T.J., Carey, E.J., et al. Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl 15 (2009), 1872–1881.
3. Samuel, D., Forns, X., Berenguer, M., Trautwein, C., Burroughs, A., Rizzetto, M., et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12–14, 2006). J Hepatol 45 (2006), 127–143.
4. Berenguer, M., Aguilera, V., Rubín, A., Ortíz, C., Jimenez, M., Prieto, M., Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol 56 (2012), 1310–1316.
5. Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008), 924–926.
6. Pawlotsky, J.P., Aghemo, A., Back, D., Dusheiko, G., Forns, X., Puoti, M., Sarrazin, C., EASL recommendations on treatment of hepatitis C 2015. J Hepatol 66 (2016), 153–194.
7. Burra, P. Panel members, Burroughs, A.K., Graziadei, I., Pirenne, J., Valdecasas, J.C., Muiesan, P., Samuel, D., Forns, X., EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 64 (2016), 433–485.
8. Hepatitis C guidance. AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. AASLD/IDSA HCV Guidance Panel. Hepatology 62 (2015), 932–954.
9. Curry, M.P., Forns, X., Chung, R.T., Terrault, N.A., Brown, R., Fenkel, J.M., et al. Sofosbuvir and Ribavirin prevent recurrence of HCV infection after liver transplantation: an open label study. Gastroenterology 148 (2015), 100–107.
10. Afdhal N, Everson G, Calleja JL, et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. Presented at the 49th Annual Meeting of the European Association for the Study of the Liver, London, April 9–13, 2014. Abstract.
11. Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
12. Manns, M., Samuel, D., Gane, E.J., Mutimer, D., McCaughan, G., Buti, M., SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with geotype 1 or 4 hepatitis C infection and advanced liver disease: a multicenter, open label, randomized, phase 2 trial. Lancet Infect Dis 16 (2016), 685–697.
13. Foster, G.R., Irving, W.L., Cheung, M.C.M., Walker, A.J., Hudson, B.E., Verma, S., et al. Cohort study of the impact of direct antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
14. Curry, M.P., O'Leary, J.G., Bzowej, N., Muir, A.J., Korenblat, K.M., Fenkel, J.M., et al. ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
15. Poordad, F., Schiff, E.R., Vierling, J.M., Landis, C., Fontana, R.J., Yang, R., et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 63 (2016), 1493–1505.
16. Saxena, V., Nyberg, L., Pauly, M., et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology 62 (2015), 715–725.
17. Sulkowski MS HCV-HIV co-infected patients: no longer a 'special' population?. Liver Int 36 (2016), 43–46.
18. Kardashian, A.A., Price, J.C., Hepatitis C virus-HIV-coinfected patients and liver transplantation. Curr Opin Organ Transplant 20 (2015), 276–285.
19. Jang, J.W., Choi, J.Y., Kim, Y.S., Woo, H.I., Choi, S.K., Lee, C.H., et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology 61 (2015), 1809–1820.
20. Coilly A, Pageaux GP, Houssel-Debry P, Duvoux C, Radenne S, de Ledinghen V at al. Improving liver function and delisting of patients awaiting liver transplantation for cirrhosis: do we ask too much to DAAs? Presented at 66th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 13–17 2015.
21. Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, Castells L et al. Interferon free antiviral therapy in cirrhotic patients infected with hepatitis c on the waiting list for liver transplantation. Efficacy and impact on delisting and liver function. Abstracts of The International Liver Congress (TM) 2016–51th Annual meeting of the European Association for the Study of the Liver .
22. Belli, L.S., Berenguer, M., Cortesi, P., Strazzabosco, M., Rockenschaub, S.R., Martini, S., et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 65 (2016), 524–531.
23. Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals. J Hepatol 65 (2016), 727–733.
24. Reig, M., Marino, Z., Perello, C., Inarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected early tumor recurrence in patients with hepatitis C virus- related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
25. Camma, C., Cabibbo, G., Craxi, A., Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol 65 (2016), 861–862.
26. The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma. J Hepatol 65 (2016), 734–740.
27. Donato, M.F., Morelli, C., Romagnoli, R., Invernizzi, F., Mazzarelli, C., Iemmolo, R.M., et al. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy. Liver Int 37 (2017), 678–683.
28. Buti, M., Riveiro-Barcela, M., R Esteban. Management of direct-acting antiviral agent failures. J Hepatol 63 (2015), 1511–1522.
29. Pawlotsky, J.M., Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151 (2016), 70–86.
30. De Luca, L., Westbrook, R., Tsochatzis, E.A., Metabolic and cardiovascular complications in the liver transplant recipient. Ann Gastroenterol 28 (2015), 183–192.
31. Duvoux, C., Pageaux, G.P., Immunosuppression in liver transplant recipients with renal impairment. J Hepatol 54 (2011), 1041–1054.
32. http://www.hep-druginteractions.org.
33. Ojo, A.O., Held, P.J., Port, F.K., Wolfe, R.A., Leichtman, A.B., Young, E.W., et al. Chronic renal failure after transplantation of a nonrenal organ. N Eng J Med 349 (2003), 731–940.
34. Selzner, N., Guindi, M., Renner, E.L., Berenguer, M., Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 55 (2011), 207–221.
35. Picciotto, F.P., Tritto, G., Lanza, A.G., Addario, L., De Luca, M., Di Costanzo, G.G., et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 46 (2007), 459–465.
36. Jensen, D.M., O'Leary, J.G., Pockros, P.J., Sherman, K.E., Kwo, P.Y., Mailliard, M.E., et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: realworld experience in a diverse, longitudinal observational cohort. Hepatology, 60, 2014, 219A.
37. Kwo, P.Y., Mantry, P.S., Coakley, E., Te, H.S., Vargas, H.E., Brown, R. Jr, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 371 (2014), 2375–2382.
38. Charlton, M., Gane, E., Manns, M.P., Brown, R.S. Jr, Curry, M.P., Kwo, P.Y., et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 148 (2015), 108–117.
39. Gutierrez, J.A., Carrion, A.F., Avalos, D., O'Brien, C., Martin, P., Bhamidimarri, K.R., et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl 21 (2015), 823–830.
40. Faisal, N., Bilodeau, M., Aljudaibi, B., Hirsch, G., Yoshida, E.M., Hussaini, T., et al. Sofosbuvir-based antiviral therapy is highly effective in recurrent hepatitis C in liver transplant recipients: Canadian multicenter “real-life” experience. Transplantation 100 (2016), 1059–1065.
41. Brown, R.S. Jr, O'Leary, J.G., Reddy, K.R., Kuo, A., Morelli, G.J., Burton, J.R. Jr, et al., Hepatitis C Therapeutic Registry Research Network Study Group. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl 22 (2016), 24–33.
42. Pungpapong, S., Aqel, B., Leise, M., Werner, K.T., Murphy, J.L., Henry, T.M., et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 61 (2015), 1880–1886.
43. Forns, X., Charlton, M., Denning, J., McHutchison, J.G., Symonds, W.T., Brainard, D., et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. Hepatology 61 (2015), 1485–1494.
44. Ciesek, S., Proske, V., Otto, B., Pischke, S., Costa, R., Lüthgehetmann, M., et al. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. Transpl Infect Dis, 18, 2016.
45. Leroy, V., Dumortier, J., Coilly, A., Sebagh, M., Fougerou-Leurent, C., Radenne, S., et al., Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO23 Compassionate Use of Protease Inhibitors in Viral C in Liver Transplantation Study Group. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol. 13 (2015), 1993–2001.
46. Fontana, R.J., Brown, R.S., Moreno-Zamora, A., Prieto, M., Joshi, S., Londoño, M.C., et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl, 2016, 10.1002/lt.24416.
47. Colombo M, Aghemo A, Liu L, Hyland R, Yun C, Brainard D, et al. Ledipasvir/sofosbuvir for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infection Abstracts of The International Liver Congress (TM) 2016–51th Annual meeting of the European Association for the Study of the Liver.
48. Ramírez, S., Pérez-Del-Pulgar, S., Forns, X., Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl 14 (2008), S27–S35.
49. Mazzaferro, V., Regalia, E., Pulvirenti, A., Tagger, A., Andreola, S., Pasquali, M., et al. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proc 29 (1997), 519–521.
50. Terrault, N., Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 26 (2012), 531–548.
51. Vinaixa, C., Rubín, A., Aguilera, V., Berenguer, M., Recurrence of hepatitis C after liver transplantation. Ann Gastroenterol 26 (2013), 304–313.
52. Chen, T., Jia, H., Li, J., Chen, X., Zhou, H., Tian, H., New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transpl Int, 2009, 408–415.
53. Duvoux, C., Tran Ngoc, A., Intrator, L., Hézode, C., Germanidis, G., Pawlotsky, J.M., et al. Hepatitis C virus (HCV)-related cryoglobulinemia after liver transplantation for HCV cirrhosis. Transpl Int 1 (2002), 3–9.
54. Hézode, C., Duvoux, C., Germanidis, G., Roudot-Thoraval, F., Vincens, A.L., Gaulard, P., et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology 30 (1999), 775–778.
55. Duvoux, C., Pageaux, G.P., Vanlemmens, C., Roudot-Thoraval, F., Vincens-Rolland, A.L., Hézode, C., et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 74 (2002), 1103–1109.
56. Lucey, M.R., Terrault, N., Ojo, L., Hay, J.E., Neuberger, J., Blumberg, E., et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 19 (2013), 3–26.
57. Blé, M., Aguilera, V., Rubín, A., García-Eliz, M., Vinaixa, C., Prieto, M., et al. Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. Liver Transpl 20 (2014), 25–34.
58. Hsu, Y.C., Lin, J.T., Ho, H.J., Kao, Y.H., Huang, Y.T., Hsiao, N.W., et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 59 (2014), 1293–1302.
59. Rosen, H.R., Retransplantation for hepatitis C: implications of different policies. Liver Transpl 6 (2000), S41–S46.
60. Burton, J.R. Jr, Sonnenberg, A., Rosen, H.R., Retransplantation for recurrent hepatitis C in the MELD era: maximizing utility. Liver Transpl 10 (2004), S59–S64.
61. Lefrere, J.J., Sellami, F., Larderie, P., Lemaillot, C., Roudot-Thoraval, F., Claquin, J., Six years of experience in virus screening of organ donors in France. Transfusion 37 (1997), 565–566.
62. Bucci, J.R., Matsumoto, C.S., Swanson, S.J., et al. Donor hepatitis C seropositivity: Clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 13 (2002), 2974–2982.
63. Saab, S., Ghobrial, R.M., Ibrahim, A.B., Kunder, G., Durazo, F., Han, S., et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant 3 (2003), 1167–1172.
64. Northup, P.G., Argo, C.K., Nguyen, D.T., McBride, M.A., Kumer, S.C., Schmitt, T.M., et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int 23 (2010), 1038–1044.
65. Montenovo, M.I., Dick, A.A., Hansen, R.N., Donor hepatitis C sero-status does not impact survival in liver transplantation. Ann Transplant 22 (2015), 44–50.
66. Kucirka, L.M., Singer, A.L., Ros, R.L., Montgomery, R.A., Dagher, N.N., Segev, D.L., Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant 10 (2010), 1238–1246.
67. Khapra, A.P., Agarwal, K., Fiel, M.I., Kontorinis, N., Hossain, S., Emre, S., et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl 12 (2006), 1496–1503.
68. Reese, P.P., Abt, P.L., Blumberg, E.A., Goldberg, D.S., Transplanting hepatitis C-positive kidneys. N Engl J Med 373 (2015), 303–305.